127 studies found for:    "Leiomyosarcoma"
Show Display Options
Rank Status Study
1 Completed Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma
Conditions: Uterus Leiomyosarcoma;   Soft Tissue Leiomyosarcoma
Interventions: Drug: Doxorubicin;   Drug: Trabectedin
2 Completed
Has Results
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Conditions: Leiomyosarcoma;   Uterine Neoplasm
Intervention: Drug: gemcitabine, docetaxel, doxorubicin
3 Active, not recruiting Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
Conditions: Leiomyosarcoma;   Uterine Neoplasm
Intervention: Drug: Letrozole
4 Active, not recruiting Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma
Condition: Leiomyosarcoma
Interventions: Drug: gemcitabine + docetaxel;   Drug: trabectedin
5 Recruiting Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
Conditions: Liposarcoma;   Leiomyosarcoma
Intervention: Drug: Trabectedin
6 Recruiting Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas
Condition: Leiomyosarcoma
Intervention: Drug: pazopanib + gemcitabine
7 Recruiting Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum
Conditions: Retroperitoneal Liposarcoma;   Retroperitoneal Leiomyosarcoma;   Chondrosarcoma
Intervention: Drug: Nilotinib-adriamycin
8 Recruiting A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Condition: Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin;   Drug: Dacarbazine
9 Active, not recruiting
Has Results
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin;   Drug: Dacarbazine
10 Unknown  Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -
Condition: Relapsed or Metastatic Uterine Leiomyosarcomas or Carcinosarcomas
Interventions: Drug: Pazopanib plus Gemcitabine;   Drug: Pazopanib
11 Completed
Has Results
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Condition: Leiomyosarcoma
Intervention: Drug: letrozole
12 Withdrawn Pazopanib for Treating Uterine Leiomyosarcoma
Condition: Uterine Leiomyosarcoma
Intervention: Drug: Pazopanib
13 Completed Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
Conditions: Uterine Leiomyosarcoma;   Uterine Cancer
Intervention: Drug: Docetaxel plus Gemcitabine
14 Completed Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
Conditions: Recurrent Uterine Sarcoma;   Uterine Leiomyosarcoma
Intervention: Drug: sunitinib malate
15 Active, not recruiting Nivolumab in Treating Patients With Advanced Uterine Leiomyosarcoma
Condition: Uterine Corpus Leiomyosarcoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
16 Recruiting SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Condition: Metastatic Leiomyosarcoma
Interventions: Drug: Mocetinostat;   Drug: Gemcitabine
17 Active, not recruiting
Has Results
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
Conditions: Recurrent Uterine Corpus Sarcoma;   Uterine Corpus Leiomyosarcoma
Interventions: Drug: Alisertib;   Other: Laboratory Biomarker Analysis
18 Active, not recruiting
Has Results
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
Conditions: Recurrent Uterine Corpus Sarcoma;   Uterine Corpus Leiomyosarcoma
Interventions: Drug: Ixabepilone;   Other: Laboratory Biomarker Analysis
19 Recruiting Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma;   Uterine Corpus Leiomyosarcoma
Interventions: Other: Clinical Observation;   Drug: Docetaxel;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Drug: Gemcitabine Hydrochloride;   Biological: Pegfilgrastim
20 Completed Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
Conditions: Recurrent Uterine Corpus Sarcoma;   Stage IIIA Uterine Sarcoma;   Stage IIIB Uterine Sarcoma;   Stage IIIC Uterine Sarcoma;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Sarcoma;   Uterine Corpus Leiomyosarcoma
Interventions: Biological: Bevacizumab;   Drug: Docetaxel;   Biological: Filgrastim;   Drug: Gemcitabine Hydrochloride;   Biological: Pegfilgrastim;   Other: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years